- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02803931
Assessing the Efficacy of CardiOGoniometry (CGM) to Localise the Culprit Vessel in Mixed Vessel Disease Non-ST elevatIon Myocardial infarcTION (NSTEMI) (COGNITION)
This study aims to test the hypothesis that cardiogoniometry (CGM) is helpful to identify the site of the culprit vessel in patients with NSTEMI in comparison to 12-lead ECG.
NSTEMI constitutes a clinical syndrome subset of acute coronary syndrome which is most usually caused by atherosclerotic coronary artery disease. It is defined by "electrocardiographic (ECG) ST-segment depression or prominent T-wave inversion and/or positive biomarkers of necrosis (e.g., troponin) in the absence of ST-segment elevation and in an appropriate clinical setting (chest discomfort or angina equivalent)". The standard 12 lead ECG is not commonly sensitive at localising the site of the culprit lesion and even coronary angiography may not always be helpful as the majority of lesions will not have angiographically evident thrombus. Patients with an ACS may have multivessel disease and it is often not possible to identify the precise site of the culprit lesion. In patients with multivessel disease, interventionists will frequently target the most severe stenosis even though this is not necessarily the acute lesion.
CGM (Cardiogoniometry cardiologic explorer, Enverdis GmbH medical solutions, Germany) is a form of 3D vector electrocardiography which can provide quantitative analysis of myocardial depolarisation and repolarisation. It has CE mark and has been shown to be more sensitive and specific than standard 12-lead ECG at diagnosing stable coronary artery disease. Furthermore, recent work has shown CGM to be more sensitive at detecting patients with NSTEMI than conventional 12-lead ECG
In summary, there is evidence that CGM is more efficacious than 12-lead ECG at the diagnosis of both stable CAD and ACS. The hope is this that the clinical application can be extended to localising ischaemia in the culprit vessel and be a valuable diagnostic aid.
The primary objective of this study is to investigate the efficacy of CGM to identify the culprit vessel in patients presenting with NSTEMI. Secondary endpoint will be to evaluate the efficacy of CGM to detect a significant coronary stenosis (defined as ≥70%) as compared to a standard 12-lead ECG
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
East Yorkshire
-
Kingston upon Hull, East Yorkshire, United Kingdom, HU16 5JQ
- Castle Hill Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients admitted with NSTEMI.
- Patients who have been consented to undergo coronary angiography +/- PCI as part of their routine care by their clinician.
- Aged 18 or over.
- The patient has been informed of the nature of the study and has provided full written informed consent.
Exclusion Criteria:
- Patients unable to give informed consent including those with communication difficulties due to poor English.
- Patients with on-going chest pain at rest despite medical therapy
- Patients with haemodynamic instability and / or cardiogenic shock (defined as a sustained blood pressure of <90mmHg +/- the need for inotropic support)
- Patients with STEMI
- Those unable to perform a good quality CGM: 1) Patients who are SOB at rest; 2) Patients with very frequent ectopic beat; 3) Patients in atrial fibrillation; 4) Patients with a heart rate >150 beats/min
- Patients with previous coronary artery bypass graft surgery
- Patients who are unable to receive treatment with heparin
- Patients with significant renal impairment (defined as eGFR<30ml/min)
- Females who are or could be pregnant
Study Plan
How is the study designed?
Design Details
- Primary Purpose: DIAGNOSTIC
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Cardiogoniometry
Every patient in the study will have a cardiogoniometry recording performed by the Cardiologic Explorer whilst an inpatient on the ward.
This will then be taken for interpretation to see if it indicates what vessel is the culprit causing their NSTEMI.
The researcher interpreting the cardiogoniometry recording will be blind to the results of the ECG and the coronary angiography,
|
Cardiogoniometry cardiologic explorer, Enverdis GmbH medical solutions, Germany
|
ACTIVE_COMPARATOR: 12-lead ECG
For every patient in the study, copies of their 12-lead ECGs performed during their admission will be taken for interpretation by an independent cardiologist.
This will then be taken for interpretation to see if it indicates what vessel is the culprit causing their NSTEMI.The researcher interpreting the ECG recordings will be blind to the results of the cardiogoniometry and the coronary angiography,
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sensitivity of CGM
Time Frame: Calculated within 30 days after participant recruitment is complete.
|
The sensitivity of CGM to detect the culprit vessel will be calculated.
|
Calculated within 30 days after participant recruitment is complete.
|
Specificity of CGM
Time Frame: Calculated within 30 days after participant recruitment is complete.
|
The specificity of CGM to detect the culprit vessel will be calculated.
|
Calculated within 30 days after participant recruitment is complete.
|
Positive predictive value of CGM
Time Frame: Calculated within 30 days after participant recruitment is complete.
|
The positive predictive value of CGM to detect the culprit vessel will be calculated.
|
Calculated within 30 days after participant recruitment is complete.
|
Negative predicative value of CGM
Time Frame: Calculated within 30 days after participant recruitment is complete.
|
The negative predictive value of CGM to detect the culprit vessel will be calculated.
|
Calculated within 30 days after participant recruitment is complete.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sensitivity of ECG
Time Frame: Calculated within 30 days after participant recruitment is complete.
|
The sensitivity of CGM to detect the culprit vessel will be calculated.
|
Calculated within 30 days after participant recruitment is complete.
|
Specificity of ECG
Time Frame: Calculated within 30 days after participant recruitment is complete.
|
The specificity of ECG to detect the culprit vessel will be calculated.
|
Calculated within 30 days after participant recruitment is complete.
|
Positive predictive value of ECG
Time Frame: Calculated within 30 days after participant recruitment is complete.
|
The positive predictive value of ECG to detect the culprit vessel will be calculated.
|
Calculated within 30 days after participant recruitment is complete.
|
Negative predictive value of ECG
Time Frame: Calculated within 30 days after participant recruitment is complete.
|
The negative predictive value of ECG to detect the culprit vessel will be calculated.
|
Calculated within 30 days after participant recruitment is complete.
|
Collaborators and Investigators
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 15/YH/0270
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Coronary Syndrome
-
Yonsei UniversityRecruitingCoronary Artery Disease, Acute Coronary SyndromeKorea, Republic of
-
Meditrix CorpNational University of Ireland, Galway, Ireland; Boston Scientific Japan K.K.; Fujita Health UniversityRecruitingChronic Coronary Syndrome | Non ST Segment Elevation Acute Coronary SyndromeJapan, Ireland
-
OrbusNeichDuke Clinical Research Institute; OrbusNeich Medical K.K.CompletedCoronary Arteriosclerosis | Non ST Segment Elevation Acute Coronary SyndromeUnited States, Japan
-
Medical University of WarsawRecruitingAcute Coronary Syndrome | Chronic Coronary Syndrome | Non ST Segment Elevation Acute Coronary SyndromePoland
-
Niguarda HospitalCompletedAcute Coronary Syndrome With ST Elevation on Electrocardiogram | Acute Coronary Syndrome Without ST Elevation on Electrocardiogram | Noncritical Coronary Artery Disease Coronary Stenosis Less Than 50 Per Cent | Aortic AneurysmsItaly
-
Sohag UniversityRecruitingLeft Main Coronary Artery Disease With Acute Coronary SyndromeEgypt
-
Eli Lilly and CompanyDaiichi Sankyo, Inc.CompletedCoronary Arteriosclerosis | Acute Coronary SyndromesUnited States
-
University of PatrasCompletedCoronary Artery Disease (CAD) | Acute Coronary Syndrome (ACS)Greece
-
Deutsches Herzzentrum MuenchenDeutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)CompletedAcute Coronary Syndrome (ACS)Germany, Italy
-
Northwestern UniversityTerminatedACS - Acute Coronary SyndromeUnited States
Clinical Trials on Cardiogoniometry
-
Stiftung Institut fuer HerzinfarktforschungCompletedStable Angina Pectoris
-
Stiftung Institut fuer HerzinfarktforschungCompleted
-
Hull University Teaching Hospitals NHS TrustCompleted
-
Hull University Teaching Hospitals NHS TrustCompleted